Rapid Internal Innovation Renders U.S. Provisional Patent Application No. 63/854,935 Obsolete, Highlighting Exceptional Velocity in AI Development MESA, AZ /...
Internal Testing Yields Encouraging Results Slightly Above Industry Benchmarks for AI Skin Lesion Analysis Tools MESA, AZ / ACCESS Newswire...
Provides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation of T-cell...
Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendKing of Prussia, Pennsylvania--(Newsfile Corp. - June...
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in...
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to...
Company discusses secure image handling, privacy-focused platform architecture, and future compliance-oriented development initiatives MESA, AZ / ACCESS Newswire / June...
Company initiates structured internal testing focused on platform stability, workflow optimization, and image consistency evaluation MESA, AZ / ACCESS Newswire...
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as...
Company outlines long-term strategy surrounding AI-assisted imaging technologies and pre-screening wellness applications MESA, AZ / ACCESS Newswire / June 4,...
WASHINGTON, June 04, 2026 (GLOBE NEWSWIRE) -- The Melanoma Research Alliance (MRA), the world's leading nonprofit funder of melanoma research,...
CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, complements CNSide Diagnostics' existing CLIA certification and further...
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -...
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -...
New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet...
Company highlights streamlined body-map tracking and image management features designed to support long-term skin monitoring workflows MESA, AZ / ACCESS...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA...
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on...
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising...